Skip to main content
  • Advertise
    Want to Advertise with Us?
    Conquer welcomes advertising and sponsorship collaborations with reputable companies offering high-quality products and services to people affected by cancer.
  • Affiliated Brands
    Academy of Oncology Nurse & Patient Navigators
    The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
    Journal of Oncology Navigation & Survivorship
    The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
    The Oncology Nurse-APN/PA
    The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
  • Healthcare Providers
  • Contribute

Breast Cancer

Articles and resources on breast cancer for patients, caregivers, and family members

Our Future: “Good Girls” with Advanced Breast Cancer
After being diagnosed with advanced breast cancer at age 30, Elizabeth McSpadden was shocked by the lack of appropriate norms to address fertility and other relevant issues in young women with cancer. Read More ›

Enhertu Received Regular FDA Approval for Unresectable or Metastatic Breast Cancer

Things They Often Don’t Tell You About Breast Cancer
Diagnosed with stage II breast cancer at age 45, Lauren Schultz found herself having to navigate a new world she knew nothing about. Here, she gives specific tips she had to learn the hard way. Read More ›

Family Matters: What a Breast Cancer Diagnosis Means for Your Loved Ones

Education, Advocacy, and Empowerment Bloom Eternal at Tigerlily Foundation: An interview with Maimah Karmo about her life’s work of empowering young women with breast cancer

Preparing for Side Effects of Breast Cancer Treatments: A Guide to Common Side Effects and What You Can Do About Them

Stepping Out from Under the Umbrella of Fear
Bonnie Annis reflects on her breast cancer diagnosis, dealing with worries of cancer recurrence, using natural remedies, and how fear and stress affect our well-being. Read More ›

How My One “No” Might Have Saved My Life
At her annual mammogram, Katrina Shaw made a decision that turned into a stroke of good fortune and prevented a delay of her diagnosis of invasive ductal carcinoma. Read More ›

Fighting Barriers to Care for Other Black Women After My Breast Cancer at Age 32
Maimah Karmo was diagnosed with stage II triple-negative breast cancer at age 32. After her diagnosis, she was emboldened to fight against the injustices and inequalities black women face in navigating medical care. Read More ›

Verzenio First CDK4/6 Approved with Endocrine Therapy for Adjuvant Treatment of Early Breast Cancer
In October 2021, the FDA approved the combination of Verzenio (abemaciclib), a CDK 4/6 inhibitor, plus endocrine therapy for adjuvant treatment (after surgery) of adults with HR-positive, HER2-negative, node-positive, early breast cancer that is at high risk of recurrence. Read More ›

Page 3 of 19